Rigel Pharmaceuticals(NASDAQ) RIGL

Current Price$39.23

Market Cap$727.32M

Since IPO (2000)-94%

5 Year-6%

1 Year+101%

1 Month+19%

Rigel Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 39.31	2026-07-21

Rigel Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-4.52%	USD 41.17	2026-07-14
1 month	+19.45%	USD 32.91	2026-06-18
3 month	+29.01%	USD 30.47	2026-04-22
Year to date	-8.22%	USD 42.83	2025-12-31
1 year	+100.66%	USD 19.59	2025-07-21
3 year	+202.38%	USD 13.00	2023-07-21
5 year	-5.96%	USD 41.80	2021-07-22
Since inception	-93.8%	USD 639.85	2000-11-29

Rigel Pharmaceuticals Financials at a Glance

Market Cap

$727.32M

Revenue (TTM)

$299.77M

Net Income (TTM)

$364.23M

EPS (TTM)

$18.72

P/E Ratio

2.10

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Price

$39.23

Volume

108

Open

$39.52

Price

$39.23

Volume

108

Open

$39.52

Previous Close

$39.31

Daily Range

$38.49 - $40.09

52-Week Range

$19.51 - $52.24

Estimated Earnings Date

Aug 4, 2026

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Price

$39.23

Volume

108

Open

$39.52

Previous Close

$39.31

Daily Range

$38.49 - $40.09

52-Week Range

$19.51 - $52.24

Estimated Earnings Date

Aug 4, 2026

RIGL News

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

Maxx ChatskoApr 1, 2020

Page 1

RIGL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rigel Pharmaceuticals

Rigel makes specialty medicines for people with rare blood disorders and cancer. These treatments help patients who do not respond well to standard medical care. The company focuses on oral pills that block specific signals causing these diseases to grow.

Fighting Disease with Targeted Pills

TAVALISSE: Oral medicine that prevents the body from destroying its own blood platelets in adults with certain immune disorders.
REZLIDHIA: Targeted therapy used to treat adults with a specific type of recurring blood cancer called acute myeloid leukemia.
GAVRETO: Daily pill for adults with lung cancer and thyroid cancers that have specific genetic changes.
R289: Investigational drug being tested for bone marrow disorders known as lower-risk myelodysplastic syndromes.

New Drugs and Global Partners

Acquired US rights to GAVRETO from Blueprint Medicines Corporation in February 2024 to expand its cancer medicine portfolio.
Partnered with Eli Lilly and Company in 2021 to develop treatments for inflammatory diseases using cell-blocking technology.
Formed a strategic alliance with University of Texas MD Anderson Cancer Center in December 2023 for new cancer studies.
Licensed distribution rights to Kissei Pharmaceutical and Grifols to sell blood disorder medicines in Asia and Europe.

What Makes Rigel Different?

Rigel specializes in small-molecule drugs that target specific biological pathways, which are chemical routes diseases use to spread. This expertise allows the company to develop oral pills that are often easier for patients than hospital-based injections.

Tracking the Recent Performance

Net product sales for TAVALISSE reached $158.8 million in 2025, up 51.6% from the previous year.
Quarterly revenue grew to $69.8 million in Q4 2025, up 21.2% compared to Q4 2024.
Operating income rose to $23.2 million in Q4 2025, representing a 39.1% increase year-over-year.
Net income reached $268.1 million in Q4 2025, up 1769.2% from $14.3 million in Q4 2024.
Free cash flow hit $22 million in Q4 2025, up 51.9% from $14.5 million in Q4 2024.

The Big Picture

Rigel has evolved from a research-focused firm into a commercial company with three approved treatments for blood disorders and cancer. By combining internal drug discovery with strategic acquisitions, the company continues to broaden its reach in specialty medicine.

AI Generated • May 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

174

CEO

Raul R. Rodriguez, MBA

Website

www.rigel.com

Headquarters

South San Francisco, CA 94080, US

RIGL Financials

Key Financial Metrics (TTM)

Gross Margin

93.39%

Operating Margin

41.56%

Net Income Margin

121.51%

Return on Equity

147.03%

Return on Capital

28.21%

Return on Assets

72.18%

Earnings Yield

47.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$727.32M

Shares Outstanding

18.50M

Volume

108

Avg. Volume

396.64K

Financials (TTM)

Gross Profit

$279.95M

Operating Income

$124.58M

EBITDA

$131.28M

Operating Cash Flow

$79.27M

Capital Expenditure

$0.00

Free Cash Flow

$79.27M

Cash & ST Invst.

$146.68M

Total Debt

$45.72M

Rigel Pharmaceuticals Performance Analysis

Rigel Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 120,242,000	-19.4%
2023	2023-12-31	USD 116,882,000	-2.8%
2024	2024-12-31	USD 179,278,000	53.4%
2025	2025-12-31	USD 294,282,000	64.1%

Rigel Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	90.7%
Q3	2025-09-30	-31.7%
Q4	2025-12-31	0.5%
Q1	2026-03-31	-15.7%

Rigel Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.40	223.3%
2023	2023-12-31	USD -1.44	-57.6%
2024	2024-12-31	USD 0.99	N/A
2025	2025-12-31	USD 19.48	1870.6%

Rigel Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	420.6%
Q3	2025-09-30	-55.5%
Q4	2025-12-31	827.4%
Q1	2026-03-31	-96.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$58.82M

+10.3%

Gross Profit

$54.21M

+10.8%

Gross Margin

92.17%

N/A

Market Cap

$727.32M

N/A

Market Cap/Employee

$4.23M

N/A

Employees

172

N/A

Net Income

$8.65M

-24.4%

EBITDA

$13.69M

-2.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$146.68M

+90.3%

Total Debt

$45.72M

-25.1%

Accounts Receivable

$49.95M

+20.2%

Inventory

$11.65M

+150.1%

Long Term Debt

$15.22M

-66.8%

Short Term Debt

$30.50M

+99.7%

Return on Assets

72.18%

N/A

Return on Invested Capital

30.01%

N/A

Free Cash Flow

$2.73M

+405.2%

Operating Cash Flow

$2.73M

+405.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OMEROmeros Corporation

OMEROmeros Corporation$9.53-1.04%

FDMT4D Molecular Therapeutics, Inc.

FDMT4D Molecular Therapeutics, Inc.$11.38+2.57%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$8.75+0.92%

VTYXVentyx Biosciences, Inc.

VTYXVentyx Biosciences, Inc.$14.00+0.00%

OLMAOlema Pharmaceuticals, Inc.

OLMAOlema Pharmaceuticals, Inc.$11.59+2.11%

AKBAAkebia Therapeutics, Inc.

AKBAAkebia Therapeutics, Inc.$1.30+1.56%

BCYCBicycle Therapeutics plc

BCYCBicycle Therapeutics plc$4.16+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$35.14+0.24%

TAT&T

TAT&T$22.26+0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.31-0.06%

NOKNokia

NOKNokia$10.63+0.05%

SKHYSK Hynix

SKHYSK Hynix$171.94+0.14%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.23+0.05%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$37.67+0.02%

Questions About RIGL

What is the current price of Rigel Pharmaceuticals?

Rigel Pharmaceuticals is trading at $39.31 per share.

What is the 52-week range for Rigel Pharmaceuticals?

Over the past 52 weeks, Rigel Pharmaceuticals has traded between $19.51 and $52.24.

How much debt does Rigel Pharmaceuticals have?

As of the most recent reporting period, Rigel Pharmaceuticals reported total debt of $45.72M.

How much cash does Rigel Pharmaceuticals have on hand?

Rigel Pharmaceuticals reported $24.41M in cash and cash equivalents in its most recent financial results.

What is Rigel Pharmaceuticals’s dividend yield?

Rigel Pharmaceuticals does not currently have a dividend yield.

Rigel Pharmaceuticals(NASDAQ) RIGL

Rigel Pharmaceuticals Financials at a Glance

RIGL News

Rigel (RIGL) Q2 Revenue Jumps 176%

Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?

3 Biotech Stocks That Could Rocket Higher

Why Rigel Pharmaceuticals Stock Jumped Today

3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring

Why Rigel Pharmaceuticals Stock Is Jumping Today

Why Rigel Pharmaceuticals Stock Skyrocketed 91% Today

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

RIGL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Rigel Pharmaceuticals

Fighting Disease with Targeted Pills

New Drugs and Global Partners

What Makes Rigel Different?

Tracking the Recent Performance

The Big Picture

RIGL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Rigel Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RIGL

What is the current price of Rigel Pharmaceuticals?

What is the 52-week range for Rigel Pharmaceuticals?

How much debt does Rigel Pharmaceuticals have?

How much cash does Rigel Pharmaceuticals have on hand?

What is Rigel Pharmaceuticals’s dividend yield?

Premium Investing Services